Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS1 known ✓ | P23219 | 1/20 | 0.41 |
| ▸ | CACNA1B known ✓ | Q00975 | 1/20 | 0.38 |
| ▸ | SLC7A11 | Q9UPY5 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | APBA1 | Q02410 | 1/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 2/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.35 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.35 |
| ▸ | GRIK1 | P39086 | 2/20 | 0.32 |
| ▸ | GRIK2 | Q13002 | 2/20 | 0.32 |
| ▸ | POLB | P06746 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL7208268 | 1.00 | PTGS1 (0.41) | PTGS1SLC7A11MAPTCACNA1BAPBA1 | |
| Hydrochloric Acid SCHEMBL9680613 | 1.00 | PTGS1 (0.41) | PTGS1SLC7A11MAPTCACNA1BAPBA1 | |
| SCHEMBL1271312 | 0.98 | PTGS1 (0.43) | PTGS1SLC7A11MAPTCACNA1BAPBA1 | |
| SCHEMBL2355766 | 0.98 | PTGS1 (0.43) | PTGS1SLC7A11MAPTCACNA1BAPBA1 | |
| SCHEMBL27781736 | 0.94 | PTGS1 (0.45) | PTGS1SLC7A11MAPTCACNA1BAPBA1 | |
| SCHEMBL3808776 | 0.82 | TDP1 (0.38) | PTGS1SLC7A11MAPTCACNA1BAPBA1 | |
| SCHEMBL16703744 | 0.82 | TDP1 (0.38) | PTGS1SLC7A11MAPTCACNA1BAPBA1 | |
| Hydrochloric Acid SCHEMBL6573325 | 0.82 | MAPT (0.39) | MAPTCACNA1BAPBA1CYP3A4TSHR | |
| Hydrochloric Acid SCHEMBL2302935 | 0.82 | MAPT (0.39) | MAPTCACNA1BAPBA1CYP3A4TSHR | |
| Hydrochloric Acid SCHEMBL2302945 | 0.82 | MAPT (0.39) | MAPTCACNA1BAPBA1CYP3A4TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6613896-B1 | Sugar is derivatized to provide a heterocycle which is then aromatized; anticarcinogenic agents; efficiency; no hazardous wastes formed | ICN PHARMACEUTICALS, INC. | 2003-09-02 | — | — | US | claimed |
| EP-1000075-A4 | METHOD OF PRODUCING TIAZOFURIN AND OTHER C-NUCLEOSIDES | ICN PHARMACEUTICALS (US) | 2001-09-05 | — | — | EP | claimed |
| EP-1000075-A1 | METHOD OF PRODUCING TIAZOFURIN AND OTHER C-NUCLEOSIDES | ICN Pharmaceuticals, Inc. (US) | 2000-05-17 | — | — | EP | claimed |
| WO-1999000399-A9 | METHOD OF PRODUCING TIAZOFURIN AND OTHER C-NUCLEOSIDES | ICN PHARMACEUTICALS (US) | 1999-04-15 | — | — | WO | claimed |
| WO-1999000399-A1 | METHOD OF PRODUCING TIAZOFURIN AND OTHER C-NUCLEOSIDES | ICN PHARMACEUTICALS, INC. (US) | 1999-01-07 | — | — | WO | claimed |
| CN-101851186-B | Method for synthesizing cilastatin sodium | UNIV ZHEJIANG NORMAL | 2012-11-14 | — | — | CN | disclosed |
| CN-101851186-A | Method for synthesizing cilastatin sodium | UNIV ZHEJIANG NORMAL | 2010-10-06 | — | — | CN | disclosed |
| EP-0680327-B1 | THERAPEUTIC USES AND DELIVERY SYSTEMS OF DEHYDROEPIANDROSTERONE | ENDORECH INC (CA) | 2004-09-15 | — | — | EP | disclosed |
| US-5955455-A | SEX STEROID PRECURSORS SUCH AS DEHYDROEPIANDROSTERONE AND DEHYDROEPIANDROSTERONE SULPHATE ARE UTILIZED FOR THE TREATMENT OF VAGINAL ATROPHY, HYPOGONADISM, DIMINISHED LIBIDO, LOSS OF COLLAGEN OR CONNECTIVE TISSUES IN THE SKIN, AND, IN | ENDORECHERCHE, INC. (CA) | 1999-09-21 | — | — | US | disclosed |
| US-5948434-A | ADMINISTERING DEHYDROEPIANDROSTERONE OR DEHYDROEPIANDROSTERONE SULPHATE VIA TRANSDERMAL PATCH | ENDORECHERCHE, INC. (CA) | 1999-09-07 | — | — | US | disclosed |
| US-5922700-A | KIT FOR DRUG DELIVERY OF STEROIDS | ENDORECHERCHE, INC. (CA) | 1999-07-13 | — | — | US | disclosed |
| US-5872114-A | Therapeutic methods and delivery systems utilizing sex steroid precursors | ENDORECHERCHE, INC. (CA) | 1999-02-16 | — | — | US | disclosed |
| US-5824671-A | VAGINAL ATROPHY, HYPOGONADISM AND LOSS OF COLLAGEN OR CONNECTIVE TISSUES | ENDORECHERCHE INC (CA) | 1998-10-20 | — | — | US | disclosed |
| US-5807849-A | INHIBITING URINARY INCONTINENCE | ENDORECHERCHE, INC. (CA) | 1998-09-15 | — | — | US | disclosed |
| US-5798347-A | DEHYDROEPIANDROSTERONE AND DEHYDROEPIANDROSTERONE SULFATE USED FOR INHIBITING PROLIFERATION OF OVARIAN CANCER | ENDORECHERCHE, INC. (CA) | 1998-08-25 | — | — | US | disclosed |
| US-5780460-A | ADMINISTERING DEHYDROEPIANDROSTERONE OR SULFATE TO TREAT MENOPAUSE, VAGINAL ATROPHY, AND OSTEOPOROSIS | ENDOREOHERCHE, INC. (CA) | 1998-07-14 | — | — | US | disclosed |
| US-5776923-A | TREATMENT WITH SEX STEROIDS | ENDORECHERCHE, INC. (CA) | 1998-07-07 | — | — | US | disclosed |
| US-5728688-A | TREATMENT OF MENOPAUSE, VAGINAL ATROPHY, HYPOGONADISM AND DIMINISHED LIBIDO | ENDOREOHERCHE, INC. (CA) | 1998-03-17 | — | — | US | disclosed |
| EP-0680327-A1 | THERAPEUTIC USES AND DELIVERY SYSTEMS OF DEHYDROEPIANDROSTERONE | ENDORECHERCHE INC. (CA) | 1995-11-08 | — | — | EP | disclosed |
| WO-1994016709-A2 | THERAPEUTIC USES AND DELIVERY SYSTEMS OF DEHYDROEPIANDROSTERONE | ENDORECHERCHE INC. (CA) | 1994-08-04 | — | — | WO | disclosed |